“Patterson Companies was significantly undervalued by the market, particularly given its $4 billion animal health division. Trading at half the multiple of its primary peer despite comparable core dental profitability, the stock represented a classic mispricing. This thesis was ultimately validated through a private equity acquisition at a significant premium in mid-December.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.